Charles Chau

Partner, Jones Day

Charles Chau advises on M&A, capital markets (including listings and public offerings), securities regulatory compliance, joint ventures, and other commercial transactions across Hong Kong, mainland China, and the Asia-Pacific region. Over the past 19 years, he has obtained extensive experience in a wide variety of industry sectors, including banking and financial services, health care, biotech, retail, real estate, and manufacturing. He has also represented Chinese companies on their outbound acquisitions in the United States and Europe.

Prior to joining Jones Day in 2017, Charles acted for China CNR Corporation Limited in its US$26 billion merger with CSR Corporation Limited, which was the first merger of two companies listed in both Hong Kong and Shanghai. In addition, he worked on many IPOs and securities placement transactions, including the IPOs of Sinopharm Group, China CNR Corporation, GenScript Biotech Corporation, Guodian Technology & Environment Group, China South City, BBI Life Sciences, and the A+H rights issue of China CITIC Bank.

He is currently working a number of capital markets transactions involving “new economy companies”.

The Stock Exchange of Hong Kong Limited (the “Exchange”) published the Consultation Conclusions regarding the Consultation Paper on a Listing Regime for Companies from Emerging and Innovative Sectors...
5 September 2018
Subscribe to RSS - Charles Chau